News Conference News AHA 2016 En mitad de la Marea Creciente de ECVA, los Costes del Tratamiento Deberían hacer que los Legisladores Legislasen en Materia de Prevención Yael L. Maxwell November 29, 2016
News Conference News AHA 2016 Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention Yael L. Maxwell November 29, 2016
News Conference News AHA 2016 My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial Shelley Wood November 28, 2016
News Conference News AHA 2016 ¿Dolor Muscular Secundario a las Estatinas? Según el Análisis GAUSS-3 Podría ser Genético Michael O'Riordan November 22, 2016
News Conference News AHA 2016 Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis Michael O'Riordan November 22, 2016
News Conference News AHA 2016 Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women L.A. McKeown November 17, 2016
News Conference News AHA 2016 PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad Michael O'Riordan November 15, 2016
Presentation AHA 2016 GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound Presenter: Steven E. Nissen November 15, 2016
News Conference News AHA 2016 AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR Shelley Wood November 09, 2016
News Conference News AHA 2015 Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact Todd Neale November 12, 2015
News Conference News AHA 2015 AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More Shelley Wood November 05, 2015